Urokinase-type plasminogen activator in carcinomatous pleural fluid

European Respiratory Journal

Volumn 10, Issue 7, 1997, Pages 1566-1571

  Ishikawa, H ^a,b   Satoh, H ^b   Hasegawa, S ^b   Yazawa, T ^b   Naito, T ^a,b   Yamashita, Y T ^b   Ohtsuka, M ^b   Ogata, T ^b   Kamma, H ^b  

^a TSUKUBA MEDICAL CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Carcinomatous pleuritis; Parapneumonic pleuritis; Tuberculous pleuritis; Urokinase type plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CANCER GROWTH; CANCER INVASION; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LUNG ADENOCARCINOMA; METASTASIS; PLEURA FLUID; PLEURISY; PLEURODESIS; PRIORITY JOURNAL; TUBERCULOSIS;

ADENOCARCINOMA; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOBLOTTING; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PLEURISY; TUBERCULOSIS, PLEURAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030814055     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10071566     Document Type: Article

References (26)

1. Cajot JF, Kruithof EKO, Schleuning WD, Sordat B, Bachmann F. Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer 1986; 38: 719-727.
2. Hart DA, Rehemtulla A. Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function. Comp Biochem Physiol (B) 1988; 90: 691-708.
3. Sappino AP, Busso N, Belin D, Vassalli JD. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas. Cancer Res 1987; 47: 4043-4046.
4. Suzumiya J, Hasui Y, Kohga S, Sumiyoshi A, Hashida S, Ishikawa E. Comparative study of plasminogen activator antigens in colonic carcinomas and adenomas. Int J Cancer 1988; 42: 627-632.
5. de Bruin PAF, Griffioen G, Verspaget HW, et al. Plasminogen activator profiles in neoplastic tissues of the human colon. Cancer Res 1988; 48: 4520-4524.
6. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992; 50: 871-873.
7. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50: 6827-6829.
8. Markus G, Takita H, Camiolo SM, Corasanti JG, Evers JL, Hobika GH. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Cancer Res 1980; 40: 841-848.
9. Satoh H, Kamma H, Ogata T, Hasegawa S. Local production of plasminogen activator inhibitor-1 in carcinomatous pleuritis. Acta Oncol 1994; 33: 710-711.
10. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Respir Dis 1991; 144: 187-194.
11. Philip-Joët F, Alessi MC, Philip-Joët C, et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995; 8: 1352-1356.
12. Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ, Lee LN. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. Cancer 1992; 69: 674-679.
13. Paladine W, Cunningham TJ, Sponzo R, Donavan M, Olson K, Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer 1976; 38: 1903-1908.
14. Broaddus VC, Hébert CA, Vitangcol RV, Hoeffel JM, Bernstein MS, Boylan AM. Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema. Am Rev Respir Dis 1992; 146: 825-830.
15. Light RW, MacGregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77: 507-513.
16. Satoh H, Ishikawa H, Funayama Y, Yazawa T, Ogata T, Hasegawa S. Combination cytotoxic effects of 5-fluorouracil and carboplatin against human lung cancer cell lines. Cancer Res Therapy Control 1995; 4: 199-202.
17. Hollas W, Blasi F, Boyd D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res 1991; 51: 3690-3695.
18. Wu R, Martin WR, Robinson CB, et al. Expression of mucin synthesis and secretion in human tracheobronchial epithelial cells grown in culture. Am J Respir Cell Mol Biol 1990; 3: 467-478.
19. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
20. Agrenius V, Chmielewska J, Widström O, Blombäck M. Pleural fibrinolytic activity is decreased in inflammation as demonstrated in quinacrine pleurodesis treatment of malignant pleural effusion. Am Rev Respir Dis 1989; 140: 1381-1385.
21. Strange C, Baumann MH, Sahn SA, Idell S. Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. Am J Respir Crit Care Med 1995; 151: 508-515.
22. Light RW. Pleural diseases. 2nd Edn. Philadelphia, Lea & Febiger, 1990; pp. 97-115.
23. Vladutiu AO. Pleural effusion. Mount Kisco, NY, Futura, 1986; pp. 175-205.
24. Rodriguez-Panadero F, Segado A, Juan JM, Ayerbe R, Garcia IT, Castillo J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785-790.
25. Stoppelli MP, Verde P, Grimaldi G, Locatelli EK, Blasi F. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent rumor promoter, phorbol myristate acetate. J Cell Biol 1986; 102: 1235-1241.
26. Laiho M, Keski-Oja J. Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 1989; 49: 2533-2553.